COL8A1 (Collagen Type VIII Alpha 1 Chain)

Moreover, its restricted expression profile supports its potential utility as a diagnostic and prognostic biomarker. Collectively, these advances position type VIII collagen as a multifunctional ECM regulator with substantial promise for disease diagnostics, therapeutic innovation, and biomaterial engineering.

Our findings identify COL8A1 as an innovative oncogenic driver in PCa that promotes tumor progression via modulation of the ADAMTS2-FAK/PI3K/AKT axis and immune infiltration. COL8A1 may be a potential prognostic biomarker and therapeutic target for PCa.

By connecting tumor-intrinsic inflammation to immunological surveillance and treatment resistance, our study identified COL8A1 as a crucial inflammatory hub in glioma. In order to improve the results of immunotherapy for glioma, COL8A1 may be a useful therapeutic target and prognostic biomarker.

Functionally, COL8A1 promotes mesenchymal phenotypes, enhances CRC cell migration and invasion in vitro, and promotes tumor growth in vivo. Collectively, our findings uncover a previously unrecognized FOSL2-COL8A1-EMT regulatory axis that fuels CRC progression and metastasis, providing novel mechanistic insights into EMT maintenance and nominating COL8A1 as a promising prognostic biomarker and therapeutic target for advanced colorectal cancer.

Mechanistically, COL6A2 silencing restored DCs' activation and enhanced the infiltration and function of effector immune cells. Our findings highlight COL6A2 as a key oncogenic and immunomodulatory ECM component in GBM and suggest that targeting collagen-mediated immune suppression may improve therapeutic outcomes in GBM patients.

Its transient inhibition facilitates early EndMT via NF-kB/Snail signaling, whereas its later induction in advanced disease reflects endothelial remodeling within atherosclerotic lesions. These findings identify COL8A1 as both a biomarker and potential therapeutic target in vascular disease.

Notably, in vitro experiments, including western blot, colony formation, CCK-8, and Transwell assays, confirmed that one key PRG, COL8A1, promotes STAD cell proliferation and migration. Collectively, our findings highlight the clinical and biological significance of PRGs in STAD, offering novel biomarkers and potential therapeutic targets for STAD precision treatment.

Computational analysis of putative ligand-receptor interactions reveals novel ECM communication networks between cancer cells and stromal components, particularly in regions of GBM microvascular proliferation and pseudopalisading necrosis. In summary, this comprehensive spatial map provides new insights into microenvironmental control of GBM initiation and progression and identifies potential therapeutic targets in the ECM.

These findings provide valuable insights into the molecular mechanisms of gastric cancer recurrence and offer potential biomarkers for prognosis and treatment response prediction. The study highlights the importance of integrating genomic data with clinical information to improve patient stratification and personalised treatment strategies in gastric cancer management.

Overall, our study reveals two circRNAs that might have a potential role in primary to metastasis transition in the BRAF-mutated melanoma within TIME via the circRNA-miRNA-mRNA axis.

Notably, both SERPINE1 expression level and SERPINE1+ fibroblast abundance correlate with malignant progression and prognosis. These findings provide a spatially resolved framework of TME remodeling, offering insights for thyroid cancer diagnosis and treatment.

Based on the investigation, we confirmed that matrix stiffness governs the progression of nasopharyngeal carcinoma and that LPAR3 and COL8A1, as matrix stiffness related biomarkers, promote nasopharyngeal carcinoma metastasis by inducing epithelial-mesenchymal transition and angiogenesis. Overall, the in-depth exploration of matrix stiffness may provide a strategy for clinical treatment intervention and provide promising targets for clinical nasopharyngeal carcinoma treatment.